Proton pump inhibitors (PPIs) may cause gastric cancer – clinical consequences

References

• Cheung KS, Chan EW, Wong AYS, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment forHelicobacter pylori: a population-based study. Gut. 2018;67:28–35.
   PubMed Web of Science ®Google Scholar
• Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Fossmark R. Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man. Gut. 2018;67:199–200.
   PubMed Web of Science ®Google Scholar
• Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986;35 Suppl 1:42–55.
   PubMed Web of Science ®Google Scholar
• Poynter D, Pick CR, Harcourt RA, et al. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut. 1985;26:1284–1295.
   PubMed Web of Science ®Google Scholar
• Elder JB. Inhibition of acid and gastric carcinoids. Gut. 1985;26:1279–1283.
   PubMed Web of Science ®Google Scholar
• Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology. 1985;88:638–648.
   PubMed Web of Science ®Google Scholar
• Zamcheck N, Grable E, Ley A, et al. Occurrence of gastric cancer among patients with pernicious anemia at the Boston City hospital. N Engl J Med. 1955;252:1103–1110.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Fossmark R, Bakke I, et al. Hypergastrinemia in animals and man: causes and consequences. Scand J Gastroenterol. 2004;39:505–509.
   PubMed Web of Science ®Google Scholar
• Soga J, Koro T, Tazawa K, et al. Argyrophil cell microneoplasia in the Mastomys' stomach-an observation on early carcinoid formation. J Natl Cancer Inst. 1975;55:1001–1006.
   PubMedGoogle Scholar
• Azzopardi JG, Pollock DJ. Argentaffin and argyrophil cells in Gastric Carcinoma. J Pathol Bacteriol. 1963;86:443–451.
   PubMedGoogle Scholar
• Wilander E, El-Salhy M, Pitkanen P. Histopathology of gastric carcinoids: a survey of 42 cases. Histopathology. 1984;8:183–193.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Haugen OA, Isaksen C, et al. Enterochromaffin-like tumour cells in the diffuse but not the intestinal type of gastric carcinomas. Scand J Gastroenterol Suppl. 1991;180:165–169.
   PubMedGoogle Scholar
• Barrett P, Hobbs RC, Coates PJ, et al. Endocrine cells of the human gastrointestinal tract have no proliferative capacity. Histochem J. 1995;27:482–486.
   PubMedGoogle Scholar
• Tielemans Y, Willems G, Sundler F, et al. Self-replication of enterochromaffin-like cells in the mouse stomach. Digestion. 1990;45:138–146.
   PubMed Web of Science ®Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathologica Et Microbiologica Scandinavica. 1965;64:31–49.
   PubMedGoogle Scholar
• Waldum HL, Aase S, Kvetnoi I, et al. Neuroendocrine differentiation in human gastric carcinoma. Cancer. 1998;83:435–444.
   PubMed Web of Science ®Google Scholar
• Qvigstad G, Sandvik AK, Brenna E, et al. Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. Histochem J. 2000;32:551–556.
   PubMedGoogle Scholar
• Qvigstad G, Qvigstad T, Westre B, et al. Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. Apmis. 2002;110:132–139.
   PubMed Web of Science ®Google Scholar
• Qvigstad G, Falkmer S, Westre B, et al. Clinical and histopathological tumour progression in ECL cell carcinoids (ECLomas)). Apmis. 1999;107:1085–1092.
   PubMed Web of Science ®Google Scholar
• Bakkelund K, Fossmark R, Nordrum I, et al. Signet ring cells in gastric carcinomas are derived from neuroendocrine cells. J Histochem Cytochem. 2006;54:615–621.
   PubMed Web of Science ®Google Scholar
• Sordal O, Qvigstad G, Nordrum IS, et al. The PAS positive material in gastric cancer cells of signet ring type is not mucin. Exp Mol Pathol. 2014;96:274–278.
   PubMed Web of Science ®Google Scholar
• Bartley AN, Rashid A, Fournier KF, et al. Neuroendocrine and mucinous differentiation in signet ring cell carcinoma of the stomach: evidence for a common cell of origin in composite tumors. Hum Pathol. 2011;42:1420–1429.
   PubMed Web of Science ®Google Scholar
• Fujiyoshi Y, Eimoto T. Chromogranin A expression correlates with tumour cell type and prognosis in signet ring cell carcinoma of the stomach. Histopathology. 2008;52:305–313.
   PubMed Web of Science ®Google Scholar
• Mjones P, Nordrum IS, Sordal O, et al. Expression of the Cholecystokinin-B receptor in neoplastic gastric cells. Horm Cancer. 2018;9:40–54.
   PubMed Web of Science ®Google Scholar
• Clerc P, Dufresne M, Saillan C, et al. Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon. Int J Cancer. 1997;72:931–936.
   PubMed Web of Science ®Google Scholar
• Fossmark R, Sordal O, Jianu CS, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36:1067–1075.
   PubMed Web of Science ®Google Scholar
• Murphy G, Abnet CC, Choo-Wosoba H, et al. Serum gastrin and cholecystokinin are associated with subsequent development of gastric cancer in a prospective cohort of Finnish smokers. Int J Epidemiol. 2017;46:914–923.
   PubMed Web of Science ®Google Scholar
• Anderson WF, Rabkin CS, Turner N, et al. The changing face of noncardia gastric cancer incidence among US Non-Hispanic Whites. J Natl Cancer Inst. 2018.DOI: 10.1093/jnci/djx262
   Google Scholar
• Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661–669.
   PubMed Web of Science ®Google Scholar
• Fiocca R, Mastracci L, Attwood SE, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther. 2012;36:959–971.
   PubMed Web of Science ®Google Scholar
• Laterza MM, Pompella L, Petrillo A, et al. Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. Med Oncol. 2017;34:186.
   PubMed Web of Science ®Google Scholar
• Niikura R, Hayakawa Y, Hirata Y, et al. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis. Gut. 2017.DOI: 10.1136/gutjnl-2017-315710
   Web of Science ®Google Scholar
• Waldum HL, Hauso O, Sordal OF, et al. Gastrin may mediate the carcinogenic effect of helicobacter pylori infection of the stomach. Dig Dis Sci. 2015;60:1522–1527.
   PubMed Web of Science ®Google Scholar
• Black JW, Duncan WA, Durant CJ, et al. Definition and antagonism of histamine H 2 -receptors. Nature. 1972;236:385–390.
   PubMed Web of Science ®Google Scholar
• Lind T, Cederberg C, Ekenved G, et al. Effect of omeprazole-a gastric proton pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut. 1983;24:270–276.
   PubMed Web of Science ®Google Scholar
• Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–1315.
   PubMed Web of Science ®Google Scholar
• Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439–1446.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Haruma K, Okamoto T, et al. Continuous proton pump inhibitor treatment decreases upper gastrointestinal bleeding and related death in rural area in Japan. J Gastroenterol Hepatol. 2012;27:372–377.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut. 1996;39:649–653.
   PubMed Web of Science ®Google Scholar
• Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80–87, 7 e1.
   PubMed Web of Science ®Google Scholar
• Nwokolo CU, Smith JT, Gavey C, et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther. 1990;4 (Suppl 1):29–45.
   PubMed Web of Science ®Google Scholar
• Havu N, Mattsson H, Ekman L, et al. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion. 1990;45:189–195.
   PubMed Web of Science ®Google Scholar
• Qvigstad G, Arnestad JS, Brenna E, et al. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. Scand J Gastroenterol. 1998;33:1244–1248.
   PubMed Web of Science ®Google Scholar
• Fossmark R, Johnsen G, Johanessen E, et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005;21:149–154.
   PubMed Web of Science ®Google Scholar
• Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther. 1999;13:145–153.
   PubMed Web of Science ®Google Scholar
• Jianu CS, Fossmark R, Syversen U, et al. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia. Tumor Biol. 2010;31:373–380.
   PubMed Web of Science ®Google Scholar